Molnupiravir has never received full FDA approval. The antiviral, sold under the brand name Lagevrio, was authorized in the United States through an Emergency Use Authorization issued in December 2021 for the treatment of mild-to-moderate COVID-19 in high-risk adults. That distinction between an EUA and full approval matters more than many people realize, and the drug’s unusual mechanism of action has kept it at the center of scientific debate ever since.
What an Emergency Use Authorization Actually Permits
An EUA allows the FDA to make a medical product available during a declared public health emergency before that product has completed the full approval process. The legal standard is lower than for traditional approval: the FDA must determine that the product “may be effective” and that the known and potential benefits outweigh known and potential risks, given the emergency. That is a meaningfully different bar from the “substantial evidence of effectiveness” required for full approval, which typically involves larger and longer clinical trials, more extensive manufacturing review, and a thorough evaluation of long-term safety data.
In practical terms, an EUA means a drug can be prescribed and distributed, but with restrictions the FDA can impose and update at any time. The authorization can also be revoked if the risk-benefit calculation changes. Patients receiving an EUA product must be informed that the drug is authorized but not approved, which is a legal requirement rather than a formality. Research suggests that this distinction creates real hesitation: a scoping review found that both the public and healthcare providers have concerns about safety or the lack of full FDA approval that may reduce willingness to accept EUA-authorized treatments.
1PubMed Central. Public and health care provider attitudes, understanding, and behaviors regarding emergency use authorizations: a scoping literature reviewFor molnupiravir specifically, the EUA was narrowly recommended by the FDA’s advisory committee in a 13-to-10 vote, reflecting genuine disagreement among experts about whether the benefits justified the risks. That close margin foreshadowed ongoing debate about the drug’s place in COVID-19 treatment.
The Clinical Trial That Led to Authorization
The EUA was primarily based on results from the MOVe-OUT trial, a large randomized study of unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 who were at high risk of progressing to severe illness. An interim analysis painted a promising picture: roughly 7% of patients on molnupiravir were hospitalized or died within 29 days, compared with about 14% on placebo. That looked like the drug was cutting the risk roughly in half.
2PubMed Central. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsBut when the full dataset was analyzed, the benefit shrank. Among all randomized participants, hospitalization or death occurred in about 6.8% of the molnupiravir group versus 9.7% of the placebo group, a difference of three percentage points rather than nearly seven. Deaths remained strikingly lopsided, with one in the molnupiravir group and nine in the placebo group, but the overall reduction in hospitalization was more modest than the interim results had suggested.
2PubMed Central. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsThat shrinkage between interim and final results is one reason the drug never progressed to full approval. The trial also enrolled only unvaccinated patients, which made the results difficult to generalize as vaccination rates climbed. A later UK trial called PANORAMIC, which studied molnupiravir in a largely vaccinated population, found that treated patients felt better, had fewer symptoms, and missed less work at six months, but the absolute differences were small and the numbers needed to treat were high.
3The Lancet. Outcomes 3 and 6 months after molnupiravir plus usual care versus usual care alone when used as early treatment for COVID-19 (PANORAMIC)How Molnupiravir Works, and Why That Raises Questions
Most antiviral drugs block a viral enzyme directly, like putting a wrench in the gears. Molnupiravir does something different and more unsettling: it introduces errors into the virus’s genetic code. After you swallow the capsule, your body converts the drug into an active compound called NHC, which cells then convert into a form that looks enough like a normal building block of RNA to fool the virus’s copying machinery.
4PubMed Central. Molnupiravir: Mechanism of action, clinical, and translational scienceThe trick is that NHC can shift between different chemical shapes, allowing it to pair with either of two RNA bases when the virus copies itself. Structural studies showed that when incorporated into viral RNA, NHC could direct the addition of either G or A into the growing strand, depending on its shape at that moment. The result is a cascade of random mutations throughout the virus’s genome. If enough errors accumulate, the virus produces defective copies of itself and the infection collapses, a process researchers call “error catastrophe” or “lethal mutagenesis.”
5PubMed Central. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesisThis approach is effective at knocking down viral replication, but it immediately raises a question that has dogged the drug since its development: if the drug works by causing mutations, could it also cause mutations in the patient’s own cells or, worse, generate new viral variants that survive and spread?
The Safety Debate Over Mutagenicity
The mutagenicity question has produced genuinely conflicting evidence, which is part of why full approval has remained elusive. In lab-based studies, molnupiravir and its active form NHC clearly caused mutations in bacteria and mammalian cell cultures. One study using a highly sensitive sequencing technique found that exposure increased mutation rates in a dose-dependent way in both bacterial and human cell lines, at concentrations comparable to what patients experience during treatment.
6PubMed. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencingHowever, in vitro results (cells in a dish) do not always translate to what happens in a living body, and more comprehensive animal studies have painted a more reassuring picture. A battery of in vivo tests, including studies specifically looking at mutations in both body cells and reproductive cells, found that molnupiravir did not increase mutation rates when given to animals at doses and durations exceeding clinical use. A carcinogenicity study in mice also came back negative.
7Toxicological Sciences. Comprehensive genotoxicity and carcinogenicity assessment of molnupiravirSeparate research using a different animal model, the roundworm C. elegans, confirmed that neither molnupiravir nor NHC increased germline mutation rates compared to controls. The researchers used whole-genome sequencing of offspring from treated worms and found no significant change in mutation frequency or type.
8PubMed. Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencingThe tension between these findings is real but has a reasonable explanation: in a living body, cells have repair mechanisms that can catch and fix the kinds of errors molnupiravir introduces. Viruses copying themselves inside cells do not have those same repair tools, which is why the drug can overwhelm the virus without necessarily doing the same to the host. Still, the short five-day treatment course was deliberately chosen to minimize potential risk, and the drug is contraindicated during pregnancy as a precaution.
Viral Evolution Concerns
The more unexpected controversy involves what molnupiravir does to the virus itself. In 2023, researchers analyzing global SARS-CoV-2 genome databases found a distinctive fingerprint of molnupiravir-induced mutations in circulating viral lineages. Branches of the viral family tree with an unusually high proportion of G-to-A and C-to-T mutations appeared almost exclusively after the drug’s introduction in 2022, and they clustered in countries and age groups where molnupiravir was widely used.
9PubMed Central. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomesThis finding means that in some patients, the drug mutated the virus heavily but did not kill it entirely, and those mutated viruses then spread to other people. A separate study of patients with prolonged infections after molnupiravir treatment found that within just 10 days, treated patients’ viruses had picked up an average of 30 new variants, with C-to-T and G-to-A mutations accounting for more than 70% of the changes. Untreated control patients showed nothing similar.
10The Lancet Microbe. Understanding SARS-CoV-2 evolution in patients with prolonged infection after molnupiravir treatmentA case-control cohort study confirmed that molnupiravir-treated patients showed a higher ratio of certain mutation types in their SARS-CoV-2 genomes within a week of starting treatment, and that this pattern matched what would be expected from the drug’s mechanism rather than from natural immune editing.
11PubMed. Molnupiravir increases SARS-CoV-2 genome diversity and complexityWhether these drug-mutated lineages actually pose a public health threat is debated. Most heavily mutated viruses are probably so damaged they are less fit, not more. But the finding that some survived and spread is uncomfortable, because it means a drug designed to destroy the virus through mutations could, in a small number of cases, be accelerating viral evolution instead. This concern became one of the strongest arguments against granting full approval.
How Molnupiravir Compares to Paxlovid
The other major oral COVID-19 antiviral, nirmatrelvir/ritonavir (sold as Paxlovid), received its own EUA around the same time and went on to receive full FDA approval in 2023. That divergence in regulatory outcomes reflects the fact that Paxlovid showed larger reductions in hospitalization and death in its pivotal trial and works through a different, less controversial mechanism: it directly blocks a viral enzyme rather than introducing mutations.
Reviews comparing the two drugs have generally found that both reduce illness and death, but Paxlovid appears to be more effective overall.
12PubMed. A tale of two drugs: Molnupiravir and PaxlovidMolnupiravir has one practical advantage, though: it does not interact with other medications. Paxlovid contains ritonavir, a drug that interferes with the liver enzymes responsible for breaking down a long list of common medications, including certain blood thinners, heart drugs, immunosuppressants, and psychiatric medications. In a study of cancer patients, roughly 30% of those given Paxlovid either experienced side effects or had to stop another medication to avoid dangerous interactions, compared with 0% for molnupiravir.
13PubMed Central. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer PatientsFor progression to severe disease in that same cancer-patient study, the rates were roughly 3% for Paxlovid versus 7% for molnupiravir. While the difference was not statistically significant given the sample size, the trend favored Paxlovid. The key takeaway is that molnupiravir carved out its niche largely as the option for patients who cannot safely take Paxlovid because of drug interactions, which is a common situation among older adults and people with complex medical conditions.
13PubMed Central. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer PatientsCost and Global Access
The economics of molnupiravir have varied dramatically depending on where in the world you live. In the United States, the government purchased about 3.1 million courses of molnupiravir for approximately $2.2 billion by early 2022, working out to roughly $700 per course of treatment.
14PubMed Central. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USFor low- and middle-income countries, the picture was different. Merck entered into a voluntary licensing agreement with the Medicines Patent Pool that allowed generic manufacturers to produce the drug at substantially reduced prices. Through that arrangement, a full course of generic molnupiravir was priced at around $20, compared with about $25 for generic Paxlovid negotiated through a separate agreement.
15PubMed Central. A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countriesThat 35-fold price difference between the US government purchase price and the generic price in lower-income countries reflects the broader economics of pandemic therapeutics, where wealthy nations paid premium prices partly to incentivize rapid development while licensing agreements tried to ensure broader access. Whether $700 per course was cost-effective in the US depended heavily on assumptions about who was being treated and what the alternative was. In high-risk unvaccinated patients, the math looked more favorable; in vaccinated populations where the absolute benefit was smaller, the value proposition got harder to justify.
Why Public Confusion About EUAs Matters
The distinction between an EUA and full approval may sound like regulatory fine print, but it has real consequences for public trust and health behavior. Research into how people perceive EUA-authorized products has consistently found that the emergency label makes people more cautious. When the public hears that a product is “authorized but not approved,” many interpret that as meaning the product is experimental, unproven, or potentially unsafe, even when the actual evidence base is substantial.
1PubMed Central. Public and health care provider attitudes, understanding, and behaviors regarding emergency use authorizations: a scoping literature reviewHealthcare providers share some of these concerns. The same review found that clinicians, too, express reservations about prescribing EUA products, particularly when a fully approved alternative exists. For molnupiravir, this dynamic was compounded by the fact that Paxlovid did eventually receive full approval while molnupiravir did not, making it the less reassuring option on two fronts: both less effective in head-to-head comparisons and lacking the regulatory stamp that signals thorough long-term review.
The EUA framework was designed for speed during crises, and it delivered on that promise. Molnupiravir went from early clinical testing to authorized use in under two years. The tradeoff is that speed comes with less certainty, and the public is not wrong to notice that gap. The challenge for healthcare communication is helping people understand that “not fully approved” does not mean “unsafe,” while also being honest that the evidence base is genuinely thinner than it would be for a fully approved drug. Molnupiravir sits squarely in that uncomfortable middle ground: a drug with real benefits for specific patients, real concerns about its mechanism, and a regulatory status that never progressed beyond the emergency that created it.
Where Molnupiravir Stands Now
Molnupiravir’s trajectory illustrates how a drug can be scientifically interesting, clinically useful in specific situations, and still fail to clear the bar for full approval. The narrowly positive advisory committee vote, the shrinking efficacy numbers between interim and final trial results, the viral evolution findings, and the availability of a stronger competitor in Paxlovid all worked against it. In countries where it was available through generic licensing, it served as an accessible oral antiviral for populations with limited treatment options. In the US, its role steadily narrowed to patients who could not take Paxlovid, and its long-term regulatory future remained tied to whether the risk-benefit balance could justify the unique concerns raised by its mutation-based mechanism.
For patients prescribed molnupiravir, the drug’s five-day course and lack of drug interactions remain genuine advantages. It is taken as four capsules twice a day, does not require dose adjustments for kidney or liver function, and can be started without worrying about interactions with blood pressure medications, blood thinners, or immunosuppressants. Those practical features explain why it continued to be used even as its broader limitations became clearer. The drug’s story is ultimately a case study in what happens when a pandemic forces regulators, clinicians, and the public to make decisions under uncertainty, and then to revisit those decisions as better evidence arrives.